Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)

Compare
36.26
+0.96
+(2.72%)
At close: April 3 at 3:00:03 PM GMT+8
Loading Chart for 688513.SS
  • Previous Close 35.30
  • Open 34.55
  • Bid 36.26 x --
  • Ask 36.27 x --
  • Day's Range 34.43 - 36.58
  • 52 Week Range 28.11 - 46.84
  • Volume 7,697,576
  • Avg. Volume 1,989,203
  • Market Cap (intraday) 6.401B
  • Beta (5Y Monthly) 0.10
  • PE Ratio (TTM) 25.36
  • EPS (TTM) 1.43
  • Earnings Date --
  • Forward Dividend & Yield 0.58 (1.60%)
  • Ex-Dividend Date Jul 1, 2024
  • 1y Target Est --

Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.

www.eastonpharma.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688513.SS

View More

Performance Overview: 688513.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688513.SS
20.35%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

688513.SS
4.37%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

688513.SS
5.04%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

688513.SS
31.66%
SSE Composite Index (000001.SS)
20.91%

Compare To: 688513.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688513.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    6.40B

  • Enterprise Value

    5.16B

  • Trailing P/E

    25.43

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.87

  • Price/Book (mrq)

    2.39

  • Enterprise Value/Revenue

    3.95

  • Enterprise Value/EBITDA

    19.43

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.54%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    8.96%

  • Revenue (ttm)

    1.35B

  • Net Income Avi to Common (ttm)

    236.57M

  • Diluted EPS (ttm)

    1.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.41B

  • Total Debt/Equity (mrq)

    6.24%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 688513.SS

View More

Company Insights: 688513.SS

Research Reports: 688513.SS

View More

People Also Watch